MD Stripped of DEA License After Abusing Drugs on Patients
Published Date: 9/19/2025
Notice
Summary
Dr. Haroon Hameed from Maryland lost his DEA license because he abused drugs while treating patients and lied on his renewal application. The DEA decided his actions put the public at risk, so they revoked his registration and denied any future applications. This means he can’t legally prescribe controlled substances anymore, effective immediately.
Analyzed Economic Effects
2 provisions identified: 1 benefits, 1 costs, 0 mixed.
DEA Registration Revoked; No Future Approval
The Drug Enforcement Administration revoked Haroon Hameed, M.D.'s DEA registration and denied any future DEA registration applications, effective immediately. This means Dr. Hameed cannot legally possess or prescribe controlled substances anymore under his DEA registration.
No Material Falsification Finding on Renewal
The DEA concluded the Government did not prove material falsification of Dr. Hameed's October 31, 2021 DEA renewal application under 21 U.S.C. 824(a)(1). The agency found two false statements in his application but determined they were not shown by clear, unequivocal, and convincing evidence to be material.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-11526 — Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 2018: Dispensing and Administering Controlled Substances for Medication-Assisted Treatment
Starting July 9, 2026, new rules make it easier for doctors and pharmacies to provide medicine that helps people recover from opioid addiction. These changes affect healthcare providers by expanding who can give medication-assisted treatment and how pharmacies can deliver these medicines. The goal? Faster, safer access to treatment with clear rules that save time and support recovery.
2026-10128 — Revision of Applications for Manufacturing and Procurement Quotas
The DEA wants to update how companies apply for permission to make and buy certain controlled drugs and chemicals. These changes will make the rules clearer, help prevent drug shortages, and ensure enough supply for medical and scientific needs. If you’re a manufacturer or involved in this process, get ready to follow new steps and share your thoughts by July 20, 2026.
2026-11909 — Importer of Controlled Substances Application: Cerilliant Corporation
Cerilliant Corporation wants to become an official importer of certain controlled substances, including some drugs that need strict government oversight. People and companies involved with these substances can share their thoughts or ask for a hearing by July 15, 2026. This move could affect how these drugs enter the U.S. and might impact businesses handling them.
2026-11572 — Ashley Vermillion, N.P.; Decision and Order
Ashley Vermillion, a nurse practitioner from Maine, lost her DEA registration because she no longer has the legal right to handle controlled substances in her state. She didn’t ask for a hearing, so the DEA moved forward and officially revoked her registration. This means she can’t prescribe or manage controlled drugs anymore, effective immediately.
2026-11416 — Importer of Controlled Substances Application: CalCog Inc.
CalCog Inc. wants to become an official importer of some powerful controlled substances like LSD and 5-MeO-DMT. People and companies involved with these drugs have until July 8, 2026, to share their thoughts or ask for a hearing. This move could shake up the import scene, but no costs or changes happen until the DEA decides.
2026-10380 — Schedules of Controlled Substances: Placement of Diphenidine in Schedule I
The DEA wants to put diphenidine, a drug, into Schedule I, which means it will be treated like the most tightly controlled substances. This change affects anyone who makes, sells, studies, or owns diphenidine, adding strict rules and penalties. You’ve got until June 25, 2026, to share your thoughts before the new rules might kick in.
Previous / Next Documents
Previous: 2025-18171 — Eric Andersen, D.D.S.; Decision and Order
Eric Andersen, a dentist from Illinois, lost his DEA license to handle controlled substances because he no longer has the state permission to do so. He didn’t ask for a hearing to challenge this, so the DEA officially revoked his registration in 2025. This means he can’t legally prescribe or manage controlled drugs anymore, effective immediately.
Next: 2025-18173 — Combined Notice of Filings #1
The Federal Energy Regulatory Commission got new electric rate requests from companies like Bel Air Solar and Atem Energy, aiming to start new rates this fall. These changes could affect energy prices and projects starting between October and November 2025. If you want to speak up or get involved, you’ve got until early October to file your comments or protests.